Alnylam Pharmaceuticals, Inc. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.8B+113.7% YoYTTM through 30 Jun 2026
Net Income $774.7MTTM through 30 Jun 2026
Free Cash Flow $465.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 81.6% |
| EBITDA Margin | 21.1% |
| Operating Margin | 13.5% |
| Net Margin | 16.1% |
Returns
39.8%ROE
6.3%ROA
118.0%ROIC
Balance Sheet Health
Debt / Equity1.28x
Current Ratio3.13x
Net Debt-$1.9Bnet cash position
Cash & Equivalents$1.7B
Quality Metrics
Altman Z-Score5.34
FCF Margin9.7%
Rule of 4024.1
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $3.7B
Diluted EPS$5.74TTMFY2025: $2.33
Dividend
No dividend
Capital Allocation
R&D Spend$1.5B
Capex Intensity1.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Transthyretin (TTR) Franchise | $2.5B | +103.0% | View detailsContinued expansion driven by the landmark approval and launch of AMVUTTRA for ATTR-CM in the U.S. |
| Rare Disease Franchise | $500M | +18.0% | View detailsSteady growth supported by increasing patient numbers globally. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.